Clinical trials: Disease, Hodgkin
Diffuse Large B Cell Lymphoma
Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma
This is a Phase I/II Trial of Decitabine + R-CHOP in Diffuse Large B-Cell Lymphoma
- Trial name
- DR-CHOP (NCT02951728)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Ruijin Hospital
DLBCL
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of MabThera® and TL011, in combination with CHOP in…
- Trial name
- NCT01205737
- Testing
- TL011, Rituximab
- Where
- 41 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 186 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Lymphoma, Non-Hodgkin, Hodgkin Disease
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or…
- Trial name
- NCT01555853
- Testing
- Abraxane
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
B-cell Lymphoma, Non Hodgkin Lymphoma
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.
- Conditions
- B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT05653271
- Testing
- Cyclophosphamide, Fludarabine, ACE1831
- Where
- 13 sites in United States, Hong Kong and 1 more
- Volunteers
- 16 people
- Sponsor
- Acepodia Biotech, Inc.
Lymphoma, B-Cell, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies.
- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT03162536
- Testing
- Nemtabrutinib
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Non-Hodgkin Lymphoma
Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)
Eligible candidates will be adults with aggressive or very aggressive NHL (WHO classification diagnosis confirmed by histological tumor examination).
- Trial name
- NCT00626444
- Testing
- Intravenous vitamin C
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Diffuse Large-cell B-cell Lymphoma
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
The purpose of this study is to investigate the safety and effectiveness of plamotamab when it is given with tafasitamab and lenalidomide in participants with relapsed or refractory DLBCL.
- Trial name
- NCT05328102
- Testing
- Plamotamab, Tafasitamab, Lenalidomide
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Xencor, Inc.
Lymphoma
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radiation to them without harming normal cells.
- Trial name
- NCT00005592
- Testing
- 90-Y-ibritumomab tiuxetan, rituximab, indium In 111 ibritumomab tiuxetan
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Alabama at Birmingham
Leukemia, Hodgkins Disease
Blood Samples to Evaluate Biomarkers of Donor Chimerism
We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants.
- Conditions
- Leukemia, Hodgkins Disease, Non-hodgkins Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT00764829
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed or Refractory B Cell Leukemia and Lymphoma
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
- Trial name
- NCT06834529
- Testing
- CAR2219-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
B Acute Lymphoblastic Leukemia
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
A chimeric antigen receptor gene-modified T cells (CART: 4SCAR19)by targeted the CD19 (cluster of differentiation antigen 19), treat patients with CD19 positive malignant B cells tumor, assess treatment safety, and observe…
- Trial name
- NCT02968472
- Testing
- prophylactic 4SCAR19 cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First People's Hospital of Yunnan
Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1
PMCF Study Fortilink-TC Ti
This study is setup to be able to gather information on the safety and performance of the Fortilink-TC Ti cage of Paradigm Spine GmbH, up to one year after the surgery.
- Trial name
- NCT07834931
- Testing
- Transforaminal lumbar interbody fusion surgery
- Where
- 2 sites in Spain
- Volunteers
- 50 people
- Sponsor
- BAAT Medical Products B.V.
Central Nervous System Lymphoma, Non-Hodgkin Lymphoma
Secondary Central Nervous System Lymphoma Registry - Charité
The objective of the observation is to collect and document data on treatment strategies for secondary central nervous system lymphoma (SCNSL) in routine clinical practice, whether obtained in the context of clinical trials or…
- Trial name
- NCT05114330
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Charite University, Berlin, Germany
Leukemia, Lymphoma, Non-Hodgkin
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
- Conditions
- Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
- Trial name
- NCT00350181
- Testing
- Sirolimus, MMF, BCNU
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Autologous Stem Cell Transplantation
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
This study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous…
- Trial name
- NCT00396331
- Testing
- G-CSF plus plerixafor
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, T-Cell, Peripheral
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal…
- Trial name
- NCT03547700
- Testing
- Romidepsin, Ixazomib
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan Rogel Cancer Center
Leukemia, Lymphoma
Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer
RATIONALE: Studying quality of life in cancer survivors may help determine the long-term effects of hematologic cancer and may help improve the quality of life for future cancer survivors.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Quality of Life
- Trial name
- NCT00126477
- Testing
- cognitive assessment, management of therapy complications, psychosocial assessment and care
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Non-Hodgkin's Lymphoma
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
The trial is an open label Simon optimal two-stage Phase II trial of fixed doses of oral meloxicam and subcutaneous filgrastim to assess the safety and efficacy in mobilizing autologous peripheral blood stem cells (PBSC) from…
- Trial name
- NCT02078102
- Testing
- Meloxicam, Filgrastim
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sherif S. Farag
Diffuse Large Cell B-lymphoma
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
The purpose of this study is to evaluate the efficacy of ibrutinib (PCI-32765) in relapsed/refractory de novo activated B-cell (ABC) and germinal-cell B-Cell (GCB) Diffuse Large B-cell Lymphoma (DLBCL).
- Trial name
- NCT01325701
- Testing
- ibrutinib
- Where
- 15 sites in United States
- Volunteers
- 78 people
- Sponsor
- Pharmacyclics LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.